This prospective, single-arm, open-label feasibility study will assess the safety, tolerability, and effectiveness of repetitive transcranial magnetic stimulation (rTMS) in patients with major depression (MDD) to test the hypothesis that remission rates can be increased by additional treatment sessions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
The treatment will be delivered by trained medical personnel.
Toronto Western Hospital
Toronto, Ontario, Canada
RECRUITINGBeck Depression Inventory-II (BDI-II) (score 0-63, higher = more severe)
Outcome measured by a change in depression score at baseline, before every treatment, and at 1 and 4 weeks post-treatment. A 50% improvement in the score is considered a response to rTMS. A score of 12 or less is categorized as remission.
Time frame: Baseline (week prior to treatment), on each treatment day, 1 week and 4 weeks post-treatment
Hamilton Depression Rating Scale 17-items (HDRS17) (score 0-52, higher = more severe)
Outcome measured by a change in depression score from baseline (week prior to treatment) to 1 week and 4 weeks post-treatment. A 50% improvement in the score is considered a response to rTMS. A score of 7 or less is categorized as remission.
Time frame: Baseline (week prior to treatment) and after 1 week and 4 weeks post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.